500221-74-9 Usage
Description
(2-Fluoro-benzyl)-pyridin-3-ylmethyl-amine is an organic compound characterized by its unique molecular structure, which features a fluoro-benzyl group attached to a pyridin-3-ylmethyl-amine moiety. (2-fluoro-benzyl)-pyridin-3-ylmethyl-amine exhibits significant potential in the pharmaceutical industry due to its specific interactions with biological targets.
Uses
Used in Pharmaceutical Industry:
(2-Fluoro-benzyl)-pyridin-3-ylmethyl-amine is used as an HIV aspartyl protease inhibitor for the treatment of HIV/AIDS. Its molecular structure allows it to effectively bind to and inhibit the aspartyl protease enzyme, which is crucial for the replication of the HIV virus. By inhibiting this enzyme, the compound can help to slow down the progression of the disease and improve the quality of life for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 500221-74-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,0,2,2 and 1 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 500221-74:
(8*5)+(7*0)+(6*0)+(5*2)+(4*2)+(3*1)+(2*7)+(1*4)=79
79 % 10 = 9
So 500221-74-9 is a valid CAS Registry Number.
500221-74-9Relevant articles and documents
Optimized chemical probes for REV-ERBα
Trump, Ryan P.,Bresciani, Stefano,Cooper, Anthony W. J.,Tellam, James P.,Wojno, Justyna,Blaikley, John,Orband-Miller, Lisa A.,Kashatus, Jennifer A.,Boudjelal, Mohamed,Dawson, Helen C.,Loudon, Andrew,Ray, David,Grant, Daniel,Farrow, Stuart N.,Willson, Timothy M.,Tomkinson, Nicholas C. O.
, p. 4729 - 4737 (2013/07/19)
REV-ERBα has emerged as an important target for regulation of circadian rhythm and its associated physiology. Herein, we report on the optimization of a series of REV-ERBα agonists based on GSK4112 (1) for potency, selectivity, and bioavailability.(1) Potent REV-ERBα agonists 4, 10, 16, and 23 are detailed for their ability to suppress BMAL and IL-6 expression from human cells while also demonstrating excellent selectivity over LXRα. Amine 4 demonstrated in vivo bioavailability after either iv or oral dosing.
